Participants
dystrophies, lens opacity, optic disc lesions, retinal or glaucoma, uveitis, Diabetic Retinopathy, retinal and macular dystrophies, corneal haziness, cataract, ocular pathologies, vitreous hemorrhage, hypersensitivity, vision loss
UNCONTROLLED HYPERTENSION, DYSTROPHIES, SCAR, UVEITIS, DIABETIC RETINOPATHY, RETINA, EYE, CATARACT, CHOROIDAL NEOVASCULARIZATION, DIABETIC MACULAR EDEMA, VITREOUS HEMORRHAGE, HYPERSENSITIVITY, TYPE 2 DIABETES MELLITUS
The present study population comprised patients aged at least 18 years with vision loss caused by type 2 diabetes mellitus presenting to the retina clinic of Feiz Eye Hospital affiliated to Isfahan University of Medical Sciences. The eligibility criteria consisted of having center-involving diabetic macular edema (CI-DME) diagnosed with spectral domain optical coherence tomography (SD-OCT) (SECTRALIS, Heidelberg), a central subfield thickness (CST) of at least 320 μm and a baseline best-corrected visual acuity (BCVA) of at most 20/50 Snellen chart, approximately equivalent to 65 Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores [The exclusion criteria encompassed uncontrolled hypertension, history of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections and focal/grid/pan-retinal laser photocoagulation of at most 3 months in the study eye prior to the first visit, history of intravitreal or peribulbar corticosteroid injections over the previous 6 months and prior suprachoroidal corticosteroid injections or intravitreal corticosteroid implants in the study eye, having the study eye undergo a cataract surgery within the previous 3 months or a significant lens opacity confirmed through expert examinations potentially requiring surgeries within the following 6 months, history of retinal or glaucoma surgery in the study eye, requiring anti-glaucoma drops for lowering IOP, other ocular pathologies in the study eye with potential inadvertent effects on the visual and anatomical outcomes, including corneal haziness and dystrophies, uveitis, retinal and macular dystrophies, active proliferative diabetic retinopathy with or without vitreous hemorrhage, choroidal neovascularization, macular scar and optic disc lesions, systemic conditions contraindicating to using corticosteroids, hypersensitivity to TA or bevacizumab, pregnancy and breastfeeding.